红细胞游离α-血红蛋白池:监测β-地中海贫血中间型变异性的生物标志物——ALPHAPOOL研究
本研究旨在验证红细胞裂解液中可溶性α-血红蛋白池作为α/非α珠蛋白生物合成比例替代指标的有效性。结果显示α-Hb池测量可良好区分β-地贫中间型患者、对照和α-地贫患者(P<0.003),曲线下面积0.978,阈值120 ppm时灵敏度86%、特异度100%。
要点
- α-Hb池测量可区分β-地贫中间型、对照与α-地贫患者,P<0.003。
- 阈值120 ng游离α-Hb/mg总Hb/ml溶血物时,AUC 0.978,灵敏度86%、特异度100%。
- α-Hb池与β-地贫生物学参数显著相关,与红细胞己糖激酶活性关联最显著。
核心结论
- α-Hb池可能成为辅助β-地贫中间型诊断导向的新标志物,并可能临床用于监测珠蛋白合成失衡对治疗的反应。
研究设计与样本
- 本研究通过测量裂解红细胞中可溶性α-Hb池,验证其作为α/非α珠蛋白生物合成比例替代指标的有效性。
主要发现
- α-Hb池测量可良好区分β-地贫中间型患者、对照和α-地贫患者(P<0.003)。
- 受试者工作特征分析显示,阈值120 ng游离α-Hb/mg总Hb/ml溶血物(ppm)时曲线下面积0.978,区分β-地贫与非β-地贫受试者的灵敏度和特异度分别为86%和100%。
- α-Hb池与β-地贫生物学参数显著相关,与红细胞己糖激酶活性关联最显著。
关键数值与推荐
- α-Hb池阈值120 ng游离α-Hb/mg总Hb/ml溶血物(ppm)时,区分β-地贫与非β-地贫的AUC为0.978,灵敏度86%、特异度100%。
- α-Hb池测量区分β-地贫中间型患者、对照和α-地贫患者的P<0.003。
临床怎么用
- 原文结论指出α-Hb池可能辅助β-地贫中间型患者的诊断导向,并可能临床用于监测珠蛋白合成失衡对治疗的反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The severity of β-thalassaemia (β-thal) intermedia is mainly correlated to the degree of imbalanced α/non α-globin chain synthesis. The phenotypic diversity of β-thal depends on this imbalance and reflects all possible combinations of α- and β-globin genotypes, levels of fetal haemoglobin (HbF) and co-inheritance of other modulating factors. This study aimed to demonstrate the validity of a new surrogate of α/non α-globin biosynthetic ratio by measuring the soluble α-Hb pool in lysed red blood cells. Our results confirm that the α-Hb pool measurement allows a good discrimination between β-thal intermedia patients, controls and α-thal patients (P < 0·003). Receiver operator characteristic analyses revealed an area under the curve of 0·978 for the α-Hb pool measurement at a threshold of 120 ng free α-Hb/mg of total Hb/ml of haemolysate (ppm) with a sensitivity and specificity of 86% and 100%, respectively, to discriminate between β-thal and not β-thal subjects. Significant correlations were observed between the α-Hb pool and biological parameters of β-thal, the most significant association being observed with red cell hexokinase activity. This study indicates that the α-Hb pool could be a new marker for assistance in diagnostic orientation of β-thal intermedia patients and may be clinically useful for monitoring the evolution of the disequilibrium of globin synthesis in response to treatments.
引用
- Vasseur C, Domingues-Hamdi E, Ledudal K, et al. Red blood cells free α-haemoglobin pool: a biomarker to monitor the β-thalassemia intermedia variability. The ALPHAPOOL study. Br J Haematol. 2017. PMID: 28643346. doi:10.1111/bjh.14800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。